China Universal CNI HK Connect Innovative Drugs Industry ETF(159570.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
China Universal CNI HK Connect Innovative Drugs Industry ETF
159570.SZ
News
View More

23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

Dr. Chris Chen, CEO of WuXi Biologics, presented at the J.P. Morgan Healthcare Conference, highlighting the company's growth and achievements for 2025. WuXi Biologics plans to complete 945 integrated projects, with a significant focus on bispecific/multispecific antibodies and ADCs, which are driving revenue growth. The company has secured record-breaking deals and is expanding its global manufacturing capabilities. WuXi Biologics aims to enhance its CRDMO model to support biopharmaceutical innovators, showcasing strong client trust and a robust project pipeline.

prnewswire·
US
WXXWY
+1.60%
HK
02269
-0.60%
prnewswire·
US
WXXWY
+1.60%
HK
02269
-0.60%

Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study

Akeso Inc. reported that cadonilimab plus chemotherapy outperformed PD-1 inhibitors in a study for first-line treatment of advanced gastric cancer with PD-L1 CPS

Reuters·
HK
09926
-0.74%
Reuters·
HK
09926
-0.74%

The Hang Seng Index rose 268 points in half a day, with the 27,000 mark "gained and lost," as innovative drug stocks collectively surged. Three new stocks had a weak finish｜Hong Kong Stock Market Afternoon Session

The Hang Seng Index opened 350 points higher this morning, reaching a maximum of 27,143 points during the day, and closed at 26,877 points, up 268 points or 1.01%. Alibaba rose 3.5%, JD.com rose 1.11%, and Tencent rose 0.48%; Xiaomi, Meituan, and Baidu, on the other hand, declined. Innovative drug stocks collectively rose, with WuXi AppTec up 7.67% and CSPC PHARMA up 5.5%. Automotive stocks generally rose due to the consensus reached on electric vehicles between China and Europe, with BYD up 3.19%. The newly listed stocks today showed volatility, with Zhaoyi Innovation once rising over 53.5%

Stheadline·
Stheadline·

Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development

Wuxi Biologics (Cayman) Inc. has launched a global CRDMO platform to enhance biologics development. The platform offers comprehensive services across the biologics lifecycle, including monoclonal antibodies and viral vaccines. Key achievements include over 600 IND submissions, 25 commercial programs, and 74 Phase III projects, with high reliability metrics: 98.3% DS success rate and 100% success rate in regulatory inspections. The flexible service model allows global clients to access tailored contract services in research, development, and manufacturing.

Reuters·
US
WXXWY
+1.60%
HK
02269
-0.60%
Reuters·
US
WXXWY
+1.60%
HK
02269
-0.60%

Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial

Innovent Biologics Inc. and Ollin Biosciences reported positive Phase 1b results for IBI324 in a clinical trial for diabetic macular edema and wet age-related macular degeneration. The study showed IBI324's superior outcomes compared to faricimab, with plans to advance to global Phase 3 studies. Full results will be presented at a symposium in February 2026.

Reuters·
HK
01801
+0.56%
Reuters·
HK
01801
+0.56%
© 2026 Longbridge｜Disclaimer